anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A system and method for locating magnetic material. In one embodiment the system includes a magnetic probe (109); a power module (104) in electrical communication with the magnetic probe(100) to supply current to the magnetic probe; a sense module (108) in electrical communication with the magnetic probe to receive signals from the magnetic probe; and a processing module (computer) in electrical communication with the power module and the sense module. The processing module (computer) generates a waveform that controls the supply of current from the power module and receives a signal from the sense module that indicates the presence of magnetic material. The magnetic probe is constructed from a material having a coefficient of thermal expansion of substantially 10 -6 /°C or less and a Young's modulus of substantially 50 GPa or greater. In one embodiment magnetic nanoparticles collect in the lymph nodes. In one embodiment the particles have a mean hydrodynamic diameter of between 5-200 nm.
1283892 Hair nail and skin treating compositions I I LUBOWE 7 Jan 1971 [8 June 1970] 814/71 Heading A5B [Also in Division C5] A composition for application to hair, nails or skin comprises an aqueous solution of a quaternary ammonium compound and 0.1- 15% of at least one mucopolysaccharide or N- acetyl glucosamine. The quaternary ammonium compound may have antioxidant and antimicrobial action. Compounds specified are benzalkonium chloride, benzethonium chloride and lauryl pyridinium chloride. The mucopolysaccharide may be hyaluronic acid or chondroitin sulphate. Other ingredients specified are: p-chloro-m-xylenol, esters of hydroxybenzoic acid, imidazolidinyl urea, propylene glycol, hexylene glycol, polyethylene glycol, glucuronic acid, a nucleic acid, a tegobetaine, cystine, cysteine, cysteine hydrochloride, allantoin polygalacturonic acid, allantoin protein, watersoluble protein, hydrolysed protein, placenta extract, pantothenyl alcohol, stearic acid, isopropyl palmitate, glycerol monostearate, cetyl alcohol, ethylene diamine tetraacetic acid, lead acetate, colloidal sulphur, ethanol, glycyrol, hexachlorophene, triethanolamine, spermaceti wax, sodium citrate, mineral oil, lanolin, white petroleum, vitamin E, and gelatin. The compositions disclosed are a scalp lotion, a hair conditioner, a nail hardener, a hair colour restorer, an acne cream, a moisturizing cream and an anti-seborrheic hair conditioner.
Acute urticaria is defined as hives that persist less than 6 weeks. Some patients with acute urticaria may progressed and need urgent management at urgent care clinics and emergency rooms. Nonsedating H1-antihistamines represent the mainstay and corticosteroids and various immunosuppressive therapies are being used in severely affected patients, or for those patients who experience a poor response to antihistamines. However, even though already treated by antihistamines, the symptoms still last longer than 3 days in more than 34% of the patients. Efficacy of omalizumab in chronic spontaneous urticaria had been demonstrated in phase II and phase III studies. Clinical symptoms and signs had been significantly reduced with omalizumab as doses of 150 mg and 300 mg at 4-week intervals in patients with chronic spontaneous urticaria who remained symptomatic despite antihistamine treatment. Omalizumab had an onset of effect within a week after initiation. Thus, the investigators hypothesize that omalizumab will be effective in the treatment of severe acute urticaria as add on therapy with a fast onset of action. Objective:To investigate the efficacy and safety of omalizumab in the treatment of severe acute urticaria Study design: This prospective, interventional, single-arm open label study will recruit patients with severe acute urticaria from emergency departments, hospitalized and outpatient departments. The included patients will receive a single subcutaneous dose of 300mg omalizumab therapy. The efficacy of omalizumab will be evaluated by physical examination and assessed by Urticaria Activity Score (UAS) at baseline, 1 hour, Day 1, Day3, Day 7, and 6 weeks after omalizumab therapy. The frequency and severity of treatment-emergent adverse events will also be evaluated.
Background A curve-shaped compression paddle could reduce the pain experienced by some women at breast cancer screening. Purpose To compare curved and standard compression systems in terms of pain experience and image quality in mammography screening. Materials and Methods In this randomized controlled trial conducted between October 2021 and February 2022, participants screened at three screening sites in the Netherlands were randomized to either a curved-paddle or sham-paddle group. The sham paddle was a standard paddle that was presented as a new paddle. At a standard screening examination, one additional image was acquired with a curved or sham paddle. Pain was measured on a numerical rating scale (range, 0-10). Participants provided a pain score after compression with the standard and test paddles, resulting in two scores per participant. Differences in pain scores were compared between groups using analysis of covariance, adjusting for pain score after standard-paddle compression. Two radiographers and two radiologists performed unblinded paired comparisons of curved-paddle vs standard-paddle images, using standard image quality criteria (radiographers evaluated 1246 image pairs using 12 criteria; radiologists evaluated 320 image pairs using six criteria). The one-sample Wilcoxon signed-rank test was used to determine if there was a significant preference for either paddle. Results In total, 2499 female participants (mean age, 61.6 years ± 7.1 [SD]) were studied; 1250 in the curved-paddle group and 1249 in the sham-paddle group. The mean pain score decreased by an additional 0.19 points in the curved-paddle group compared with the sham-paddle group (95% CI: 0.09, 0.28; P < .001). In terms of image quality, the observers showed no preference or a preference for the standard paddle. Decreased image contrast (range Bonferroni-corrected P values: P < .001 to P > .99) and visibility of structures were the main concerns for curved-paddle images. Conclusion The use of the curved paddle resulted in a minimal pain reduction during mammography breast compression but image quality was reduced. © RSNA, 2024 Supplemental material is available for this article.
When the Uniform Law Commission (ULC) was recently in the process of revising the Uniform Determination of Death Act (UDDA), Neurology® ran a series of debates over certain controversial issues being deliberated. Omitted was a debate over the fundamental concept underlying brain death. In his introductory article, Bernat offered reasons for this omission: "It is not directly relevant to practicing neurologists who largely accept brain death, do not question its conceptual basis, …." In this article I argue the opposite: the fundamental concept of death is highly relevant to the clinical criteria and tests used to diagnose it. Moreover, most neurologists in fact disagree with the conceptual basis articulated by Bernat. Basically, there are 3 competing concepts of death: (1) biological: cessation of the integrative unity of the organism as a whole (endorsed by Bernat and the 1981 President's Commission), (2) psychological: cessation of the person, equated with a self-conscious mind (endorsed by half of neurologists), and (3) the vital work concept proposed by the 2008 President's Council on Bioethics. The first actually corresponds to a circulatory, not a neurologic, criterion. The second corresponds to a "higher brain" criterion. The third corresponds loosely to the UK's "brainstem death" criterion. In terms of the biological concept, current diagnostic guidelines entail a high rate of false-positive declarations of death, whereas in terms of the psychological concept, the same guidelines entail a high rate of false-negative declarations. Brainstem reflexes have nothing to do with any death concept (their role is putatively to guarantee irreversibility). By shining a spotlight on the deficiencies of the UDDA through attempting to revise it, the ULC may have unwittingly opened a Pandora's box of fresh scrutiny of the concept of death underlying the neurologic criterion-particularly on the part of state legislatures with irreconcilably opposed worldviews.
To treat hypovolemic shock, fluid infusion or blood transfusion is essential to address insufficient volume. Much controversy surrounds resuscitation in hypovolemic shock. We aimed to identify the ideal fluid combination for treating hypovolemic shock-induced swine model, analyzing bioelectrical impedance and hemodynamics. Fifteen female three-way crossbred pigs were divided into three different groups. The three resuscitation fluids were (1) balanced crystalloid, (2) balanced crystalloid + 5% dextrose water, and (3) balanced crystalloid + 20% albumin. The experiment was divided into three phases and conducted sequentially: (1) controlled hemorrhage (1 L bleeding, 60 min), (2) resuscitation phase 1 (1 L fluid infusion, 60 min), and (3) resuscitation phase 2 (1 L fluid infusion, 60 min). Bioelectrical impedance analysis was implemented with a segmental multifrequency bioelectrical impedance analyzer. A total of 61 impedance measurements were assessed for each pig at six different frequencies in five segments of the pig. Pulse rate (PR), mean arterial pressure (MAP), stroke volume (SV), and stroke volume variation (SVV) were measured using a minimally invasive hemodynamic monitoring device. The three-dimensional graph showed a curved pattern when infused with 1 L of balanced crystalloid + 1 L of 5% dextrose water and 1.6 L of balanced crystalloid + 400 ml of 20% albumin. The 1M impedance increased in all groups during the controlled hemorrhage, and continuously decreased from fluid infusion to the end of the experiment. Only balanced crystalloid + 20% albumin significantly restored MAP and SV to the same level as the start of the experiment after the end of fluid infusion. There were no significant differences in MAP and SV from the time of recovery to the initial value of 1M impedance to the end of fluid infusion in all groups. The change and the recovery of hemodynamic indices such as MAP and SV coincide with the change and the recovery of 1M impedance. Using balanced crystalloid mixed with 20% albumin in hypovolemic shock-induced swine model may be helpful in securing hemodynamic stability, compared with balanced crystalloid single administration.
PURPOSE:To obtain a pharmaceutical composition having high transcutaneous or transrectal absorptivity, by using a specific compound in combination with an unsaturated sesquiterpene alcohol as a transcutaneous absorbefacient, and using a dihydropyridine-type Ca-antagonist as an antistenocardia and hypotensive agent. CONSTITUTION:The objective composition contains (A) a transcutaneous absorbefacient consisting of (a) one or more compounds of formula I or formula II (R1-3 are lowr alkyl) and (b) an unsaturated sesquiterpene alcohol composed mainly of (+ or -)-alpha-bisabolol and (B) a dihydropyridine-type Ca-antagonist (e.g. nivadipine, nifedipine, etc.). The compound of formula I is e.g. N-methyl-2- pyrrolidone, etc., and the compound of formula II is e.g. 1,3-dimethyl-2- imidazolidinone. The combined use of the compounds (a) and (b) remarkably improves the compatibility to the drug, and the transcutaneous and transrectal absorption of the drug, and enables the use as an agent for external application or rectal administration.
BACKGROUND: Although many people with MS (pwMS) modify their diet after diagnosis, there is still no consensus on dietary recommendations for pwMS. A number of observational studies have explored associations of diet and MS progression, but no studies have systematically reviewed the evidence. This systematic review aimed to provide an objective synthesis of the evidence for associations between diet and MS progression, including symptoms and clinical outcomes from observational studies.
METHODS: We performed a systematic review following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Electronic database searches were performed for studies completed up to 26 July 2023 using PubMed (Medline), Web of Science, CINAHL, Embase (Ovid), and Scopus, followed by citation and reference list checking. We included studies using diet quality scores or dietary indices. Studies assessing individual foods, nutrients, or dietary supplements were excluded. We used the Newcastle-Ottawa Scale to assess the risk of bias of included studies.
RESULTS: Thirty-two studies met the inclusion criteria. Of these, 20 were cross-sectional and 12 prospective. The most frequent outcomes assessed were disability (n = 19), quality of life (n = 12), fatigue (n = 12), depression (n = 9), relapse (n = 8), anxiety (n = 3), and magnetic resonance imaging (MRI) outcomes (n = 4). Based on prospective studies, this review suggests that diet might be associated with quality of life and disability. There were also potential effects of higher diet quality scores on improved fatigue, disability, depression, anxiety, and MRI outcomes but more evidence is needed from prospective studies.
CONCLUSIONS: Observational studies show some evidence for an association between diet and MS symptoms, particularly quality of life and disability. However, the impact of diet on other MS outcomes remains inconclusive. Ultimately, our findings suggest more evidence is needed from prospective studies and well-designed tailored intervention studies to confirm associations.
BACKGROUND: Care of newborns hospitalized in the neonatal intensive care unit (NICU) includes multiple painful procedures/day. Epidemiologic studies have reported the frequency and nature of procedures and treatment interventions. However, evidence on the changing trends in the nature and frequency of neonatal pain procedures or treatments over time is absent or inconclusive. We aimed to determine the frequency and nature of painful procedures/neonate/day in the NICU.
DATABASES AND DATA TREATMENT: MEDLINE and Embase searches were conducted from database inception to July 2023. Studies that reported the nature and frequency of painful procedures and associated pain treatments in neonates were included. Standard inverse-variance random-effects meta-analyses were used to combine studies. Heterogeneity between studies was quantified using the I2 statistic.
RESULTS: Of 2622 unique citations, 64 full-text articles were reviewed; 23 were included. Six additional studies identified in a previous review, and six publications from reference lists were added, resulting in 35 studies. The mean number of painful procedures/neonate/day was 7.38 (95% CI 5.60, 9.17; range <2 to 17). Although the frequency of painful procedures in more recent studies was reduced, it was not statistically significant (p = 0.16). Painful procedures were more frequent during longer observation periods. Needle-related procedures were most common and did not change over time. Procedure-related treatment was suboptimal and inconsistently reported.
CONCLUSIONS: Frequency of painful procedures in the NICU has shown a clinically important decrease but has not significantly changed over time. A paradigm shift moving responsibility from providers to systems in changing pain practices in the NICU is required.
SIGNIFICANCE STATEMENT: The decrease in the daily frequency of painful procedures in hospitalized neonates might be clinically relevant but is not yet statistically significant. Pain treatment is insufficiently documented and reported. This lack of progress in neonatal care might be a result of the complexity of defining pain and stress; inconsistencies in determining the burden of procedural pain; the influence of barriers and facilitators on practice change; and the focus on an individual rather than system responsibility for pain prevention and treatment.
Patients undergo blood, saliva or tissue sample collection for mRNA analysis and drug efficacy testing. Patients assigned treatment per the results are followed every 1 cycle of therapy for 1 year, every 2 months for 1 year, every 4 months for 1 year then every 6 months thereafter.
BACKGROUND: Frailty in newly-diagnosed multiple myeloma (NDMM) patients is associated with treatment-related toxicity, which negatively affects health-related quality of life (HRQoL). Currently, data on changes in HRQoL of frail and intermediate-fit MM patients during active treatment and post-treatment follow-up are absent.
METHODS: The HOVON123 study (NTR4244) was a phase II trial in which NDMM patients ≥ 75 years were treated with nine dose-adjusted cycles of Melphalan-Prednisone-Bortezomib (MPV). Two HRQoL instruments (EORTC QLQ-C30 and -MY20) were obtained before start of treatment, after 3 and 9 months of treatment and 6 and 12 months after treatment for patients who did not yet start second-line treatment. HRQoL changes and/or differences in frail and intermediate-fit patients (IMWG frailty score) were reported only when both statistically significant (p < 0.005) and clinically relevant (>MID).
RESULTS: 137 frail and 71 intermediate-fit patients were included in the analysis. Compliance was high and comparable in both groups. At baseline, frail patients reported lower global health status, lower physical functioning scores and more fatigue and pain compared to intermediate-fit patients. Both groups improved in global health status and future perspective; polyneuropathy complaints worsened over time. Frail patients improved over time in physical functioning, fatigue and pain. Improvement in global health status occurred earlier than in intermediate-fit patients.
CONCLUSION: HRQoL improved during anti-myeloma treatment in both intermediate-fit and frail MM patients. In frail patients, improvement occurred faster and, in more domains, which was retained during follow-up. This implies that physicians should not withhold safe and effective therapies from frail patients in fear of HRQoL deterioration.
OBJECTIVE: Benign prostatic hyperplasia (BPH) is a common chronic disease affecting the health of the urinary system and the quality of life in older adults. Plasmakinetic resection of the prostate (PKRP) is one of the important surgical procedures for treating BPH; However, older adults may experience anesthesia complications and postoperative pain. This retrospective study aimed to assess the effects of preoperative oral gabapentin on anesthesia outcomes in older adults with BPH undergoing PKRP and to provide detailed clinical evidence for improving the impact of surgical treatment.
METHODS: The medical records of 178 older adults with BPH who underwent PKRP in Tianjin Hospital from March 2021 to March 2023 were retrospectively analyzed. After excluding 18 patients who did not meet the inclusion criteria, 160 patients were finally included in the study. According to preoperative use of gabapentin, patients were divided into the observation group (n = 75, received gabapentin) and the control group (n = 85, did not receive gabapentin). The baseline data, visual analog scale (VAS) scores, postoperative Ramsay Sedation Scale (RSS) scores, and incidence of adverse reactions were collected.
RESULTS: There were no significant differences observed between the two groups in terms of age, body mass index, prostate volume, surgery duration, International Prostate Symptom Score (IPSS), American Society of Anesthesiologists (ASA) classification, history of hypertension and diabetes mellitus, VAS scores at postoperative 36 hours and 48 hours, and RSS scores at postoperative 2 hours, 4 hours, 8 hours, 12 hours, 24 hours, 36 hours, and 48 hours (p > 0.05). Compared to the control group, the observation group had significantly lower VAS scores at postoperative 2 hours, 4 hours, 8 hours, 12 hours, and 24 hours (p < 0.001), and the incidence of adverse reactions was significantly lower within 24 hours after surgery (p < 0.05).
CONCLUSIONS: Preoperative administration of gabapentin before PKRP could reduce pain severity and the incidence of adverse reactions and improve anesthetic effects in older adults with BPH, which is conducive to postoperative recovery.
The invention relates to a drug for treating and preventing arthropathy and a preparation method. The temperature control, refrigeration and other biological and chemical treatments are carried out on fresh joints, ligaments, tendons and bone tissues of cold-resistant animals (dogs, geese, ducks, snow hares, bears, roe deer, deer and snow clams) and emus with very strong adaptability (Australian ostrich), thereby preparing an oral preparation-joint health and ion-introduction raw liquid after the comprehensive extraction and the enzymatic degradation. The drug can supply a cold-resistant factor and a high adaptability factor and/or activate the human immune reconstruction. The drug can adjust the human immune and an anti-rheumatism immune system, allow the varied antigens and tissues to reverse, block the pathological damages, provide the substances which are needed for the metabolism and the repair of the joints, the ligaments, the tendons and the bone tissues, repair the pathological damages and prevent or postpone the degeneration of joint aging. The drug has special effects on treating rheumatoid arthritis and wind-dampness arthralgia, preventing and treating hypertrophic arthritis and helping and accelerating the repair and the rehabilitation of the joints, the ligaments and the bone tissues. The product is safe and has no toxicity or side effect.
Autosomal dominant polycystic kidney disease (ADPKD) affects 1 in 1000 adults. Most cases result from causative PKD1 or PKD2 variants. HNF1B, GANAB and ALG9 variants are also associated with ADPKD. Recent evidence indicates that monoallelic loss-of-function (LoF) IFT140 variants are a cause for non-syndromic ADPKD. We describe 368 patients with IFT140 LoF variants and a spectrum of phenotypic findings that support the association of IFT140 with PKD. We reviewed patients with an unknown cause for their cystic disease and those with heterozygous LoF IFT140 variants classified as pathogenic or likely pathogenic from a cohort that received genetic testing using a panel of 385 renal disease-associated genes. IFT140 LoF variants were significantly enriched in patients with cystic disease when compared with those without cystic disease. A cystic phenotype was reported in 223 of the 368 (60.6%) individuals harboring an IFT140 LoF variant, 98% of which had no other identified cause for their cystic disease. Of 122 unique LoF IFT140 variants identified, 56 (46%) were frameshift, 38 (31%) nonsense, 22 (18%) splice site and 6 (5%) exon-level deletions. Only six IFT140 individuals were reported with end-stage kidney disease, consistent with observed milder clinical presentations in IFT140-related PKD. This study offers further evidence for the involvement of LoF IFT140 variants in PKD, particularly when no additional molecular etiology has been identified.